Your browser doesn't support javascript.
loading
Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab.
Lin, Jamie S; Wang, Daniel Y; Mamlouk, Omar; Glass, William F; Abdelrahim, Maen; Yee, Cassian; Abudayyeh, Ala.
Afiliación
  • Lin JS; Section of Nephrology, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Wang DY; Section of Hematology-Oncology, Department of Internal Medicine, Baylor College of Medicine, Houston, Texas, USA.
  • Mamlouk O; Section of Nephrology, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Glass WF; Department of Pathology and Laboratory Medicine, University of Texas Health Science Center McGovern Medical School, Houston, Texas, USA.
  • Abdelrahim M; Department of Medical Oncology, Institute of Academic Medicine and Weill Cornell Medical College, Houston Methodist Cancer Center, Houston, Texas, USA.
  • Yee C; Department of Melanoma Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Abudayyeh A; Department of Immunology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J Immunother Cancer ; 8(2)2020 10.
Article en En | MEDLINE | ID: mdl-33020246
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Rituximab / Antineoplásicos Inmunológicos / Inhibidores de Puntos de Control Inmunológico / Inmunoterapia Tipo de estudio: Risk_factors_studies Idioma: En Revista: J Immunother Cancer Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Rituximab / Antineoplásicos Inmunológicos / Inhibidores de Puntos de Control Inmunológico / Inmunoterapia Tipo de estudio: Risk_factors_studies Idioma: En Revista: J Immunother Cancer Año: 2020 Tipo del documento: Article